Finally, analyses of tumor samples from mRCC patients receiving sunitinib and other targeted agents via immunohistochemistry (IHC) and other methods have examined potential markers such as hypoxia-inducible factor 1-alpha (HIF-1α) [11–13]. This evidence concerns the gene HIF1A and neoplasm.